Skip to main content

Advertisement

Log in

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study which demonstrated the high prevalence of abnormal renal function in a population of 4,684 solid tumour patients. Among them, 50–60% had decreased renal function defined as CrCl below 90 and 80% were treated with anticancer drugs that either necessitated dosage adjustment in case of RI or were potentially nephrotoxic drugs. Since patients and drugs used differ depending on the type of tumour, the IRMA Study Group started analyses in different subgroups of patients. In the 1898 IRMA patients with breast cancer, the prevalence of RI was still very high in spite of a normal serum creatinine in almost all cases. Some anticancer drugs, as in particular some bisphosphonates, capecitabine and platinum salts, may be nephrotoxic and/or need dosage adjustment. However other important drugs in breast cancer do not require dose reduction, and do not present with potential nephrotoxicity (anthracyclines, taxanes, trastuzumab). Both issues seem to be slightly but significantly more important in patients with bone metastases as compared to patients with a non-metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS (1975) Increased incidence of malignancy during chronic renal failure. Lancet 1:883–886. doi:10.1016/S0140-6736(75)91684-0

    Article  CAS  PubMed  Google Scholar 

  2. Sutherland GA, Glass J, Gabriel R (1977) Increased incidence of malignancy in chronic renal failure. Nephron 18:182–184. doi:10.1159/000130762

    Article  CAS  PubMed  Google Scholar 

  3. Cengiz K (2002) Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 33:121–126. doi:10.1023/A:1014489911153

    Article  PubMed  Google Scholar 

  4. Jones CA, McQuillan GM, Kusek JW et al (1998) Serum creatinine levels in the US population: third national health and nutrition examination survey. Am J Kidney Dis 32:992–999. doi:10.1016/S0272-6386(98)70074-5

    Article  CAS  PubMed  Google Scholar 

  5. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Renal Insufficiency and Cancer Medications (IRMA) Study Group et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376–1384. doi:10.1002/cncr.22904

    Article  CAS  PubMed  Google Scholar 

  6. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2(Suppl 1)):S1–S266

    Google Scholar 

  7. Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100. doi:10.1111/j.1523-1755.2005.00365.x

    Article  PubMed  Google Scholar 

  8. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M (2007) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol Dec 7; [Epub ahead of print]

  9. Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D et al (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25(19):2678–2684. doi:10.1200/JCO.2006.09.9994

    Article  CAS  PubMed  Google Scholar 

  10. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792. doi:10.1200/JCO.2005.04.1764

    Article  CAS  PubMed  Google Scholar 

  11. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P et al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24(21):3515

    CAS  Google Scholar 

  12. Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium. San Antonio abstract 1

  13. Body JJ (2006) Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 12:6258s–6263s. doi:10.1158/1078-0432.CCR-06-0840

    Article  CAS  PubMed  Google Scholar 

  14. Tripathy AD, Diel I, Body JJ (2004) Ibandronate reduces skeletal morbidity in patients with breast cancer. Semin Oncol 31(5(Suppl 10)):64–66. doi:10.1053/j.seminoncol.2004.07.025

    Article  CAS  Google Scholar 

  15. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744. doi:10.1002/cncr.11701

    Article  CAS  PubMed  Google Scholar 

  16. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349(17):1676–1679. doi:10.1056/NEJM200310233491721

    Article  CAS  PubMed  Google Scholar 

  17. Cockcroft DW, Gault MH (1976) Prediction of CrCl from serum creatinine. Nephron 16:31–41. doi:10.1159/000130554

    Article  CAS  PubMed  Google Scholar 

  18. Levey AS, Greene T, Kusek JW (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:0828 abstract

    Google Scholar 

  19. Aronoff GR, Berns JS, Brier ME et al (1999) Drug prescribing in renal failure. Dosing guidelines for adults, 4th edn. American College of Physicians-American Society of Internal Medicine, USA

    Google Scholar 

  20. Launay-Vacher V, Karie S, Deray G (2005) GPR Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant rénal, 3rd edn. Méditions International, France

    Google Scholar 

  21. Lauro S, Lalle M, D’Andrea, Vecchione A, Frati L (1994) Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature. Anticancer Res 4(5B):171–172

    Google Scholar 

  22. Merouani A, Davidson SA, Schrier RW (1997) Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 17(1):53–58

    Article  CAS  PubMed  Google Scholar 

  23. Nikolsky E, Mehran R, Lasic Z et al (2005) Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 67:706–713. doi:10.1111/j.1523-1755.2005.67131.x

    Article  PubMed  Google Scholar 

  24. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M, International Society of Geriatric Oncology (2007) International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43:852–858. doi:10.1016/j.ejca.2006.12.006

    Article  CAS  PubMed  Google Scholar 

  25. Lichtman S, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14–34. doi:10.1016/j.ejca.2006.11.004

    Article  PubMed  Google Scholar 

  26. Launay-Vacher V, Chatelut E, Lichtman S, Wildiers H, Steer C, Aapro M (2007) Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations. Ann Oncol 18:1314–1321. doi:10.1093/annonc/mdm011

    Article  CAS  PubMed  Google Scholar 

  27. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420–432. doi:10.1093/annonc/mdm442

    Article  CAS  PubMed  Google Scholar 

  28. Body JJ, Diel IJ, Tripathy D, Bergstrom B (2006) Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15(3):299–302. doi:10.1111/j.1365-2354.2005.00641.x

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Under the direction of the IRMA Scientific Committee, the IRMA Study has been coordinated by ICAR, a National Medical Advisory Service on the interactions between drugs and the kidney (i.e. drug dosage adjustment, drug nephrotoxicity, drug–drug interactions with immunosuppressive therapies) located in the Department of Nephrology at Pitié-Salpêtrière Hospital in Paris, France. The authors are indebted to the physicians who took time from their busy work schedules to participate in the IRMA Study Group and to Roche France, thanks to whom ICAR services are available to French oncologists through an unrestricted educational grant.

IRMA Scientific Committee (Alphabetical)

P. Beuzeboc, Paris; G. Deray, Paris; J. Gligorov, Paris; V. Launay-Vacher, Paris; J.-F. Morere, Paris; S. Oudard, Paris; X. Pourrat, Tours; I. Ray-Coquard, Lyon, J.-P. Spano, Paris.

IRMA Study Group (Alphabetical)

Pr A. Adenis, Lille; Dr E. Banu, Paris; Dr P. Beuzeboc, Paris; Dr H. Boostandoost, Paris; Dr S. Clisant, Lille; Dr N. Colbert, Paris; Dr L.-M. Dourthe, Metz; Dr D. Egret, Nantes; Dr J. Egreteau, Lorient; Dr J. Gligorov, Paris; Dr J.-P. Guastalla, Lyon; Dr M.-F. Jaeger, Metz; Dr F. Joly, Caen; Dr J. Ayllon, Paris; Dr C. Le Tourneau, Paris; Dr C.-B. Levache, Périgueux; Dr A. Lortholary, Nantes; Mr C. Maguire, Périgueux; Dr A. Monnier, Montbéliard; Pr J.-F. Morere, Paris; Dr E. Ouahrani, Paris; Pr S. Oudard, Paris; Dr I. Ray-Coquard, Lyon; Pr O. Rixe, Paris; Dr E. Sevin, Caen; Dr L. Stefani, Grenoble, France.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Vincent Launay-Vacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Launay-Vacher, V., Gligorov, J., Le Tourneau, C. et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124, 745–753 (2010). https://doi.org/10.1007/s10549-008-0131-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0131-1

Keywords

Navigation